Replies to post #365 on Equity Field Notes from temporal sources

[DanWebzster]

GALT is expanding from its focus on NASH development to Oncology development with a shoestring

Early data from a combo trial with MRK 's Prembolizumab in solid tumors recently showed promise

This trial will enroll more patients

The problem is that they only have enough cash to get into Q1/19

If efforts to find a partner for their NASH program are unsuccessful, GALT will likely to go the dilute-R/S-dilute route.